Kornimate/medical-research-clean huggingface dataset:
impact of peritoneal closure and retroperitoneal drainage on patients who underwent laparotomic retroperitoneal lymph node dissection

Conditions: Lymphocele; Gynecologic Cancer

Summary: to elucidate whether peritoneal closure and retroperitoneal drainage can benefit clinical outcome of early gynecologic cancer patients who underwent retroperitoneal lymph node dissection.

to elucidate whether peritoneal closure and retroperitoneal drainage can benefit clinical outcome of early gynecologic cancer patients who underwent retroperitoneal lymph node dissection by reviewing the medical records of patients who underwent retroperitoneal lymph node dissection for stage i or ii gynecological cancer in far eastern memorial hospital, january 2011\~december 2017.

Eligibility criteria:
inclusion criteria: * stage i or stage ii gynecologic cancer (including cervical cancer, endometrial cancer, ovarian cancer, and fallopian tube cancer) * underwent laparotomic gynecologic oncologic surgery, including retroperitoneal lymphadenectomy. exclusion criteria: * nil
allopurinol in acute coronary syndrome

Conditions: Chronic Stable Angina

Summary: allopurinol is a drug commonly used to treat gout. however recent studies have shown it has the potential to help improve oxygen supply to heart muscle. in this study the investigators aim to find out if allopurinol slows down the onset of angina symptoms, as seen by a doctor on a tracing of the heart (ecg- electrocardiogram), for patients who have been diagnosed with heart disease, when exercising on a treadmill. the investigators are also are trying to figure out the best dose of allopurinol to use and to see how quickly it begins working. to do this the investigators will recruit patients with angina, exercise them on a treadmill after giving different doses of allopurinol and see if there is an improvement in their time to bring on angina symptoms and signs. patients recruited to this trial will receive three different treatment regimes over a six week period. each treatment regime will last for one week with a one week rest period between each regime. this will involve up to eleven visits to ninewells medical school, dundee for testing.


Eligibility criteria:
inclusion criteria: * angiographically documented coronary artery disease, * a positive exercise tolerance test (ett) * a history of symptoms of chronic, stable, effort-induced angina for ≥ 2 months. * all concomitant antianginal medication will be allowed and continued unchanged during the study. exclusion criteria: * the inability to do an ett due to back or leg problems, * myocardial infarction or acute coronary syndrome ≤ 2 months, * coronary revascularization (percutaneous or cabg) ≤ 6 months, * left ventricular ejection fraction \<45%, * estimated gfr \ 180 mmol/ml, * significant valvular pathology, * already had gout or on allopurinol, * atrial arrhythmias or ecg abnormalities interfering with st-segment interpretation, * previous ventricular arrhythmias on ett, * severe hepatic disease * or on azathioprine, 6 mercaptopurine or warfarin. * patients who have participated in any other clinical trial within the previous 30 days will be excluded. * patients who are unable to give informed consent will also be excluded from this trial

Keywords: allopurinol angina acute coronary syndrome
clinical trial of sodium bicarbonate to prevent contrast-induced nephropathy

Conditions: Acute Kidney Failure

Summary: the purpose of this study is to determine whether sodium bicarbonate is effective in the prevention of sodium-induced nephropathy

the use of contrast media is more frequent as new diagnostic and therapeutic procedures are developed. as a consequence, the occurrence of acute renal failure (arf), also known as contrast-induced nephropathy, is more frequently seen after the realization of these procedures, representing about 10% of all in-hospital arf. the importance of preventing this complication is related with its strong association with higher morbidity and mortality rates in patients who present it. a number of drugs and interventions have been studied for preventing contrast-induced nephropathy, including intravenous hydration with normal and hypotonic saline solutions, oral hydration, mannitol, diuretics, dopamine and its antagonists (fenoldopam), calcium antagonists, theophylline, n-acetylcysteine, natriuretic atrial peptide and hemodialysis after or during contrast media administration. there is only one study in humans that demonstrates the utility of the sodium bicarbonate to prevent the contrast-induced nephropathy, showing a reduction in the incidence of this complication of about 13.6%. although this result could seem convincing, its relevance has been questioned because the definition used by the authors as contrast-induced nephropathy was an increase of 25% from basal creatinine. although when compared, the absolute differences between basal and after-procedure creatinines were not statistically significative, the sample size was small and the participants were low-risk patients to develop contrast-induced nephropathy. it is also important to note that the control group was hydrated with a dextrose 5% solution with 154 meq of nacl, although today's most accepted prevention therapy is intravenous hydration with normal saline solution. comparison: hydration previously, during and afterwards contrast media administration with normal saline solution (0.9%), compared to hydration previous, during and afterwards contrast media administration with a solution made of normal saline and sodium bicarbonate.

Eligibility criteria:
inclusion criteria: * age over 18 years old * indication for coronariography and/or percutaneous coronary intervention * voluntary written consent for the realization of coronariography and/or percutaneous intervention and for the participation in this clinical trial * a mehran contrast-induced nephropathy score of six or more exclusion criteria: * patients with chronic kidney failure requiring any kind of dialysis * patients unable to complete follow-up * multiple myeloma * exposure to contrast 48 hours prior to study * pregnancy * patients unable to give consent * already receiving sodium bicarbonate solutions * receiving contrast media other than non-ionic

Keywords: acute kidney failure contrast-induced nephropathy non-ionic contrast media ionic contrast media iopamidol percutaneous coronary intervention coronariography
the effects of early mobilization in stroke patients on functional status, psychological distress, and quality of life

Conditions: Stroke, Acute

Summary: this study aims to investigate the effects of an early mobilization intervention in improving functional status, psychological distress, and quality of life in stroke patients. we hypothesize that this intervention method can significantly alleviate patient anxiety and depression, thereby promoting functional recovery and enhancing overall quality of life. through this research, we hope to provide stroke patients with more effective exercise programs to help them regain health and well-being.

this study employs an experimental design conducted on patients in the stroke unit of the hospital who are over 20 years old and have either ischemic or hemorrhagic stroke with stable vital signs post-stroke onset, limb muscle strength greater than 3 points, and good communication skills in chinese and taiwanese, or they can read chinese. eligible participants are divided into an experimental group and a control group. all participants receive standard stroke unit care, while the intervention group additionally undergoes a 3-day activity protocol. the primary outcomes are assessed at baseline and at 1, 4, and 12 weeks post-stroke. finally, the study analyzes the effect of early intervention on improving the prognosis of stroke patients. the data collected in this study, whether in paper form or electronically, will be documented on a computer. after completing the research report, any recordings and paper documents will be destroyed. once the data is documented, identifiable patient information will be removed, and each record will be assigned a unique code, making individual data unidentifiable.

Eligibility criteria:
inclusion criteria: * must be over 20 years old. * patients diagnosed with infarct or hemorrhagic stroke 24 to 72 hours later. -patients with stable vital signs, systolic blood pressure between 140- 220mmhg, heartbeat 40-130bpm, blood oxygen \>92%. * the muscle strength of the limbs is greater than 3 points. * can communicate in chinese and taiwanese. exclusion criteria: * patients with severe mental illness, critically ill patients and cognitive dysfunction. * surgery patients, aphasia patients. * nihss greater than 16 points for severe stroke

Keywords: stroke early mobilization
safety evaluation of clopidogrel sulfate in patients with peripheral arterial disease

Conditions: Peripheral Arterial Disease (PAD)

Summary: primary objective: * to evaluate whether 12 weeks of clopidogrel is superior to ticlopidine in terms of lower risk of the safety events of interests in patients with peripheral arterial disease (pad) secondary objectives: * to compare the risk of bleeding adverse events, serious adverse events and overall safety of clopidogrel with ticlopidine * to compare the risk of vascular events of clopidogrel with ticlopidine * to document the long-term safety of clopidogrel for a total of 52 weeks * to document the vascular events of clopidogrel for a total of 52 weeks


Eligibility criteria:
inclusion criteria: documented symptomatic peripheral arterial disease (one or both of the following two primary criteria must be satisfied): * current intermittent claudication with ankle brachial index (abi) \< 0.90 * a history of intermittent claudication together with previous related intervention in a leg exclusion criteria: * patients who had acute atherothrombotic events or any invasive therapies within 30 days before the randomization, or patients who planned any invasive therapies within 12 weeks after the randomization * bleeding diathesis, coagulopathy and present bleeding disease * previous intracranial bleeding or hemorrhagic stroke * uncontrolled hypertension the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Keywords: platelet aggregation inhibitors peripheral arterial disease (pad)
patient compliance to self-collection for detection of hpv-dna

Conditions: Compliance; Cervical Cancer

Summary: a study to investigate the compliance of unassisted women to self-collection of specimens for hybrid capture (hc) for detection of human papilloma virus (hpv) dna compared to pap smear collection by medical personnel, as screening method to identify precursor lesions of cervical cancer.

women living in the community of the morro dos macacos, vila isabel, rio de janeiro, were randomly allocated for self-collection of specimens for hc ii for detection of hpv-dna or to pap smear collection by medical personnel, as screening method to identify precursor lesions of cervical cancer. the compliance was measured by the delivery of the specimen obtained by self-collection or to attend to a visit at the community health center to be submitted to pap smear collection, within a week.

Eligibility criteria:
inclusion criteria: * women between 25-59 years-old * not pregnant * had held their last pap smear for over a year * could read. exclusion criteria: * women with previous hysterectomy * history of cervical cancer or its precursors * bearers of some state of chronic immunosuppression (such as hiv ou autoimmune diseases) * those who underwent self-collection of their specimen during menstrual period

Keywords: patient compliance hpv-dna probes papanicolaou test cervical cancer
a follow-up extension study to evaluate the persistence of immune response to gsk biologicals' hpv vaccine in healthy chinese female subjects who received three doses of the vaccine in the hpv-058 study

Conditions: Cervical Intraepithelial Neoplasia

Summary: the purpose of this study is to evaluate the persistence of immune response in subjects who received the hpv-16/18 vaccine, seven to eight years after the last dose of primary vaccination in the hpv-058 study. no new subjects will be enrolled in this extension study.


Eligibility criteria:
inclusion criteria: * subjects/subject's parents/legally acceptable representative(s) \[lar(s)\] who, in the opinion of the investigator, can and will comply with the requirements of the protocol. * written informed consent obtained from the subject or subject's parents/lar(s) prior to performing any study specific procedure. * written informed assent obtained from the subjects below the legal age of consent. * subjects who received all three doses of the hpv-16/18 vaccine in the hpv-058 study. * healthy subjects as established by medical history and clinical examination before entering into the study. exclusion criteria: * use of any investigational or non-registered product (drug or vaccine which may have an impact on the study objectives) during the period starting 30 days (day 29 to day 1) before the study visit. * concurrently participating in another clinical study, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product (pharmaceutical product or device). * previous vaccination against hpv outside the hpv-058 study. * subjects with contraindications related to blood draw such as blood disorders and anticoagulants use.

Keywords: immune response cervarix persistence chinese human papillomavirus
feasibility and utilization of an application-based question prompt list

Conditions: Financial Toxicity; Cancer; Question Prompt List

Summary: this trial studies how well an application-based question prompt list works in improving treatment cost discussion between patients with breast, prostate, lung, or colorectal cancer and their oncologists. an application-based question prompt list, called discussion of cost application (disco app), may help to improve how patients and oncologists discuss cancer treatment costs.

the overall goal of this research is to reduce financial toxicity related to the cost of cancer treatment in a diverse patient population. the research tests the feasibility of an application-based ("app") communication intervention designed to improve the frequency and quality of patient-oncologist treatment cost discussions during clinical interactions, which, in turn, should improve other short- and longer-term patient outcomes, including referrals to economic support (e.g., social work); efficacy in managing treatment cost; treatment cost distress; financial toxicity; and treatment adherence. if successful, this study will result in an evidence-based tool that can reduce financial toxicity and improve medical outcomes for a diverse patient population.

Eligibility criteria:
inclusion criteria: * medical oncologists or radiation oncologists at kci mclaren detroit, mclaren flint, mclaren macomb and mclaren port huron oncology centers * oncologists will be eligible if they treat patients with prostate, breast, lung or colorectal cancers. * oncologists will be consented * patients must be 18 yrs. old or older * patients will be consented * patients must be able to read and write in english * patients must have a confirmed diagnosis of breast, prostate, lung or colorectal cancer and are scheduled to see an oncologist for an initial treatment discussion. exclusion criteria: * n/a

Keywords: cancer treatment cost, patient-provider communication
evaluation system and clinical application for diabetic retinopathy

Conditions: Diabetic Retinopathy

Summary: diabetic retinopathy(dr) is one of the most common and serious microvascular complications of diabetes,which is the primary cause of vision loss of diabetic patients. the risk of blindness is 25 times that of healthy people.fundus fluorescein angiography (ffa) is the gold standard for diagnosing the stage of diabetic retinopathy.however,ffa is an invasive examination which requires the patient to be in good physical condition and is not suitable for large-scale screening.therefore, it is important to build up an evaluation system for early diagnosis of dr,which is more convenient, safer, and non-invasive.firstly, this study will retrospectively analyze the ffa images of dr to find the earliest and most frequently occurring fundus quadrant.secondly,based on the retrospective analysis results, a prospective comparative study will be conducted,which combines the fundus photography with optical coherence tomography angiography(angio-oct) and physical indicators to find out whether it has consistency, sensitivity and specificity with ffa in diagnosing the stage of dr in order to build up a more effective,safer and faster evaluation system and clinical application for dr.

firstly, this study will retrospectively analyze the ffa images of dr to find the earliest and most frequently occurring fundus quadrant.secondly,based on the retrospective analysis results, a prospective comparative study will be conducted,which combines the fundus photography with angio-oct and physical indicators to find out whether it has consistency, sensitivity and specificity with ffa in diagnosing the stage of dr.finally，based on all the results,to build up a more effective,safer and faster evaluation system and clinical application for dr.

Eligibility criteria:
inclusion criteria: patients with diabetic retinopathy exclusion criteria: refractive interstitial turbidity cannot cooperate with examiner retinal surgery in patients malignant tumors hematological diseases immune diseases glaucoma or other retinal diseases

Keywords: tomography, optical coherence fluorescein angiography fundus photographs
a study using l5 as a risk factor of cardiovascular (cv) disease in chronic renal and dialytic patients

Conditions: Cardiovascular Disease; Chronic Kidney Disease Patients; Hemodialytic Patients; High LDL Level; High L5 Level

Summary: the purpose of this study is to determine whether l5, one of the low density lipoproteins, is an effective predicting factor for cardiovascular disease in chronic renal and hemodialytic patients.

cardiovascular disease (cvd) is the most important cause of death of chronic kidney disease (ckd) and hemodialysis (hd) patients. low density lipoprotein (ldl) is an essential indicator of cvd.the higher the plasma ldl level, the higher the risk of cvd. ldl is a heterogenous substance composed of different mass and size. oxidized ldl (oxldl) is the oxidation product of ldl and is the most important component of ldl associated with cvd. the oxldl is mostly trapped within tissue and not easily to be detected from blood. l5 iw a kind of electronegative ldl and is associated with cvd in smokers and diabetic patients, even if these patients have normal plasma ldl. uremia patients have lipid profile different from that of general people,while hd patients have lower ldl and ckd patients have ldl higher than that of general population. thus ldl plasma level cannot fully explain the high risk of cvd in ckd and hd patients. as patients with normal ldl but high l5 are prone to have cvd, we suspect there might be association of l5 with cvd in both ckd and hd patients.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of ckd * clinical diagnosis of hd exclusion criteria: * n/a

Keywords: l5 ldl cardiovascular disease chronic kidney disease hemodialysis
study of ngm831 as monotherapy and in combination with pembrolizumab or pembrolizumab and ngm438 in advanced or metastatic solid tumors

Conditions: Pancreatic Cancer; Breast Cancer; Gastric Cancer; Non-small Cell Lung Cancer; Cervical Cancer; Endocervical Cancer; Squamous Cell Carcinoma of Head and Neck; Bladder Urothelial Cancer; Colorectal Carcinoma; Esophageal Cancer; Ovarian Cancer; Renal Cell Carcinoma; Prostate Cancer; Melanoma; Mesothelioma; Cholangiocarcinoma

Summary: study of ngm831 as monotherapy and in combination with pembrolizumab or pembrolizumab and ngm438 in advanced or metastatic solid tumors


Eligibility criteria:
inclusion criteria: * histologically or cytologically documented locally advanced or metastatic solid tumor malignancy. * adequate bone marrow, kidney and liver function * performance status of 0 or 1. * resolved acute effects of any prior therapy to baseline severity or ctcae grade 1 except for aes not constituting a safety risk by investigator judgement. exclusion criteria: * prior treatment targeting ilt3. * prior treatment targeting lair1.
study of epigenetic and inflammatory markers of accelerated biological ageing in the follow up of patients with hodgkin's lymphoma

Conditions: Hodgkin Lymphoma in Remission

Summary: study design: it is a monocentric and exploratory study, experimental on human tissues in vitro which involves the analysis of peripheral blood in patients with hodgkin's lymphomas with the following characteristics: * in complete remission for at least two years after first-line therapy with stage iib, iii or iv at onset (ann arbor classification). * newly diagnosed (stage iib, iii or iv, ann arbor classification).

the study aims to evaluate patients with hodgkin lymphoma in complete remission for at least 2 years and newly diagnosed (stage ii b, stage iii or stage iv) as they are currently characterised by a long life expectancy during which there is an increased and early incidence of non-neoplastic systemic complications as well as, of course, manifestations of secondary malignancies.

Eligibility criteria:
inclusion criteria: * hodgkin lymphoma stage ii b, iii or iv at onset in remission for at least two years after the first line of therapy for lymphoma * newly diagnosed histologically confirmed stage ii b, iii or iv patients who require first-line therapy * patients of both sexes aged ≥ 18 years at enrollment * signature of informed consent exclusion criteria: * concomitant second neoplasm

Keywords: epigenetic markers
predictors of drug hypersensitivity in hiv infected subjects

Conditions: HIV Infections; Hypersensitivity

Summary: a case-control study to look at hypersensitive and tolerant individuals matched for hla genetic predisposition, when considering predictors of drug hypersensitivity.the study aims to identify the immunological factors increasing the risk of drug reactions in hiv positive individuals.

1. to determine in a case control study clinical parameters associated with drug hsr to abacavir, nevirapine and efavirenz in hiv infected subjects. 2. to measure functional and numerical differences in dc populations and responses to tlr ligands in patients with hsr and tolerant subjects sharing genetic markers for susceptibility to hsr. 3. identify the role of different dc populations in the development of abacavir reaction by mixing and depletion studies in sensitized subjects and in in vitro assays for abacavir hypersensitivity. 4. to measure t cell parameters including t cell viability in culture, and expression of fas and fasl on blood mononuclear cells in hiv infected controls and hsr patients. 5. to measure blood t cell populations including drug reactive t cells and t regulatory cells in tolerant and reactive subjects with genetic susceptibility to abacavir and nevirapine hsr.

Eligibility criteria:
inclusion criteria: * hiv infected patients on treatment with the drugs efavirenz, nevirapine, or abacavir. * age over 18 cases are those who have had a hypersensitivity reaction, and controls are those who have had no reaction

Keywords: treatment experienced hiv